Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrated clinical experience with tolerogenic peptides

C Nicodemus1, G Philip, N Jones

  • 1ImmuLogic Pharmaceutical Corporation, Waltham, Mass. 02154, USA.

International Archives of Allergy and Immunology
|May 1, 1997
PubMed
Summary

Allergy immunotherapy using targeted peptides for cat and ragweed allergens shows clinical activity in over 2,000 patients. Higher doses demonstrated greater efficacy with minimal hypersensitivity, suggesting a novel treatment pathway for allergic diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychological and mental health factors involved in nausea and vomiting across pregnancy.

Journal of reproductive and infant psychology·2025
Same author

Systematic review: dorsal bridge plating in distal radius fractures.

Musculoskeletal surgery·2024
Same author

Laryngo- rhino- otologie·2022
Same author

Laryngo- rhino- otologie·2022
Same author

Laryngo- rhino- otologie·2022
Same author

Laryngo- rhino- otologie·2022

Area of Science:

  • Immunology
  • Allergology
  • Pharmacology

Background:

  • Allergen-specific immunotherapy aims to desensitize patients to allergens.
  • Peptide-based approaches target specific T cell epitopes for improved safety and efficacy.
  • Clinical development of targeted peptide therapies for common allergies like cat and ragweed is ongoing.

Purpose of the Study:

  • To evaluate the clinical activity and safety of peptide-derived immunotherapy for cat (Fel d 1) and ragweed (Amb a 1) allergies.
  • To investigate the mechanism of action and potential side effects of the investigational treatment.
  • To assess the impact of therapy on allergic immune responses.

Main Methods:

  • Selection of five peptides (two from Fel d 1, three from Amb a 1) based on T cell epitope mapping.

Related Experiment Videos

  • Administration of peptide regimens (75-750 microg) in 4-6 doses over 2-4 weeks to over 2,000 patients.
  • Monitoring of clinical activity, immediate hypersensitivity, and allergic symptom pathways.

    • Main Results:

    • Clinical activity demonstrated across various dose regimens, with higher doses showing greater efficacy.
    • Immediate hypersensitivity to treatment peptides was rare and manageable through patient screening.
    • A histamine-mediated, IgE-independent pathway for allergic symptoms was identified, more pronounced in cat allergies.
    • Symptoms could be ameliorated with H1 blockers, and the seasonal rise in allergen-specific IgE was blunted.

    Conclusions:

    • Peptide-derived immunotherapy for cat and ragweed allergies is clinically active and generally well-tolerated.
    • The treatment appears to modulate allergic responses through a non-IgE-dependent mechanism.
    • Further long-term studies are warranted to monitor immune responses, including antibody levels and T cell proliferation.